Exactly, thanks for that Snoball, they rushed it to a big trial without any real evidence for clinical efficacy, (they used a surrogate endpoint, always a dangerous practice) and then bombed big time. PRR on the other hand, have established clinical efficacy first, before launching Phase II/III. This is a credit to management that they are careful with shareholders money.
- Forums
- ASX - By Stock
- abagovomab vs oregovomab - facts ...
Exactly, thanks for that Snoball, they rushed it to a big trial...
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
39.0¢ |
Change
-0.005(1.27%) |
Mkt cap ! $555.5M |
Open | High | Low | Value | Volume |
40.0¢ | 40.0¢ | 39.0¢ | $342.6K | 869.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
27 | 606350 | 39.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
39.5¢ | 393754 | 22 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
28 | 617586 | 0.390 |
13 | 357119 | 0.385 |
23 | 691666 | 0.380 |
6 | 321105 | 0.375 |
12 | 535028 | 0.370 |
Price($) | Vol. | No. |
---|---|---|
0.395 | 390109 | 24 |
0.400 | 72968 | 13 |
0.405 | 63916 | 5 |
0.410 | 304517 | 7 |
0.415 | 115650 | 2 |
Last trade - 14.06pm 19/06/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
INF
INFINITY LITHIUM CORPORATION LIMITED
Ryan Parkin, Managing Director & CEO
Ryan Parkin
Managing Director & CEO
Previous Video
Next Video
SPONSORED BY The Market Online